全文获取类型
收费全文 | 6652篇 |
免费 | 404篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 114篇 |
妇产科学 | 75篇 |
基础医学 | 1055篇 |
口腔科学 | 149篇 |
临床医学 | 490篇 |
内科学 | 1448篇 |
皮肤病学 | 81篇 |
神经病学 | 785篇 |
特种医学 | 220篇 |
外科学 | 1080篇 |
综合类 | 29篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 361篇 |
眼科学 | 190篇 |
药学 | 482篇 |
中国医学 | 12篇 |
肿瘤学 | 506篇 |
出版年
2024年 | 6篇 |
2023年 | 43篇 |
2022年 | 49篇 |
2021年 | 304篇 |
2020年 | 131篇 |
2019年 | 199篇 |
2018年 | 205篇 |
2017年 | 127篇 |
2016年 | 175篇 |
2015年 | 212篇 |
2014年 | 296篇 |
2013年 | 333篇 |
2012年 | 571篇 |
2011年 | 574篇 |
2010年 | 313篇 |
2009年 | 276篇 |
2008年 | 479篇 |
2007年 | 469篇 |
2006年 | 436篇 |
2005年 | 412篇 |
2004年 | 404篇 |
2003年 | 334篇 |
2002年 | 305篇 |
2001年 | 40篇 |
2000年 | 18篇 |
1999年 | 43篇 |
1998年 | 44篇 |
1997年 | 57篇 |
1996年 | 28篇 |
1995年 | 29篇 |
1994年 | 15篇 |
1993年 | 19篇 |
1992年 | 14篇 |
1991年 | 16篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 7篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1964年 | 4篇 |
1961年 | 7篇 |
1960年 | 5篇 |
排序方式: 共有7110条查询结果,搜索用时 93 毫秒
61.
62.
Dadi Helgason Solveig Helgadottir Anders Ahlsson Jarmo Gunn Vibeke Hjortdal Emma C. Hansson Anders Jeppsson Ari Mennander Shahab Nozohoor Igor Zindovic Christian Olsson Stefan Orri Ragnarsson Martin I. Sigurdsson Arnar Geirsson Tomas Gudbjartsson 《The Annals of thoracic surgery》2021,111(4):1292-1298
63.
64.
65.
Timothy D. Lyon Igor Frank Matthew K. Tollefson Robert F. Tarrell Paras H. Shah Robert H. Thompson Robert J. Karnes Stephen A. Boorjian 《Urologic oncology》2021,39(6):370.e1-370.e8
IntroductionIntraoperative hypothermia (IOH) has been suggested to adversely impact outcomes following surgery. The objective of this study was to evaluate the association between IOH and survival following radical cystectomy (RC).MethodsPatients who underwent RC for bladder cancer from 2003 to 2018 were identified in our cystectomy registry. Intraoperative temperatures were extracted from the anesthesia record. IOH was defined as a median intraoperative temperature <36°C, and severe IOH as ≤ 35°C. Time under 36°C was assessed as a continuous variable. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were estimated using the Kaplan-Meier method. Associations between IOH and outcomes were assessed with multivariable Cox proportional hazards models.ResultsA total of 852 patients were identified, among whom 274 (32%) had IOH. Median follow up among survivors was 4.9 years (IQR 2.4–8.7), during which time 483 patients died, including 343 from bladder cancer. Two-year survival was not significantly different between patients with and without IOH (CSS: 74% vs. 71%, P= 0.31; OS: 68% vs. 67%, P= 0.13). Following multivariable adjustment, neither IOH nor time under 36°C was significantly associated with survival. A total of 37 patients (4.3%) had severe IOH. These patients were observed to have significantly lower 2-year OS (56% vs. 68%, P= 0.005); however, this association did not remain statistically significant after multivariable adjustment (P= 0.92).ConclusionIOH was not independently associated with survival following RC. These data do not support IOH as a prognostic factor for cancer outcomes among patients undergoing RC. 相似文献
66.
Vignesh T. Packiam Craig V. Labbate Stephen A. Boorjian Robert Tarrell John C. Cheville Svetlana Avulova Vidit Sharma Matvey Tsivian Brittany Adamic Mohammad Mahmoud Ryan P. Werntz Norm D. Smith R. Jeffrey Karnes Matthew K. Tollefson Gary D. Steinberg Igor Frank 《Urologic oncology》2021,39(7):436.e1-436.e8
IntroductionWhile numerous current clinical trials are testing novel salvage therapies (ST) for patients with recurrent nonmuscle invasive bladder cancer (NMIBC) after bacillus Calmette-Guérin (BCG), the natural history of this disease state has been poorly defined to date. Herein, we evaluated oncologic outcomes in patients previously treated with BCG and ST who subsequently underwent radical cystectomy (RC).MethodsWe identified 378 patients with high-grade NMIBC who received at least one complete induction course of BCG (n = 378) with (n = 62) or without (n = 316) additional ST and who then underwent RC between 2000 and 2018. Oncologic outcomes were compared using the Kaplan-Meier method and Cox proportional hazards models. Sensitivity analyses were conducted stratifying by presenting tumor stage, matched 1:3 for receipt vs. no receipt of ST.ResultsPatients receiving ST were more likely to initially present with CIS (26% vs. 17%) and less likely with T1 disease (34% vs. 50%, P = 0.06) compared to patients not treated with ST. Receipt of ST was not associated with increased risk of adverse pathology (≥pT2 or pN+) at RC (31% vs. 41%, P = 0.14). Likewise, 5-year cancer-specific survival did not significantly differ between groups on univariable Kaplan-Meier analysis (73% for ST and 74% for no ST, P = 0.7). Moreover, on multivariable analysis, receipt of ST was not significantly associated the risk of death from bladder cancer (HR 1.12; 95% CI 0.60–2.09, P = 0.7). Results were unchanged on sensitivity analysis.ConclusionsThese data suggest that, in carefully selected patients, ST following BCG for high grade NMIBC does not compromise oncologic outcomes for patients who ultimately undergo RC. 相似文献
67.
68.
69.
James D. Weinrich Ph.D. Peter J. Snyder Ph.D. Richard C. Pillard M.D. Igor Grant M.D. Denise L. Jacobson M.P.H. S. Renée Robinson R.N. M.A. M.F.C.C. J. Allen McCutchan M.D. 《Archives of sexual behavior》1993,22(2):157-168
Many researchers interested in sexual orientation can be separated into two camps: The lumpers, who try to reduce sexual classifications to as small a number of categories as possible, and the splitters, who try to show differences among groups and individuals that make classification schemes increasingly difficult and/or intricate. We report factor analyses of the Klein Grid (a questionnaire with 21 sexual orientation items) to see how many factors emerge in two samples of strikingly different origins. In both samples, the first factor to emerge loaded substantially on all of the Klein Grid's 21 items. This factor accounted for a majority of the variance. In both samples, a second, correlated factor emerged which indexed a separation between most of the items and those having to do with social and/or emotional preferences. In both samples, a third correlated factor also emerged, but this factor differed between the two populations: one refined the social/emotional distinction and the other distinguished ideal behavior from past and current behavior. We conclude on the basis of our analysis that both the lumpers and the splitters are correct.Supported by NIMH grants IP50 MH 45294 and R01 MH 43298. 相似文献
70.
Kenneth V. Honn Dean G. Tang Xiang Gao Igor A. Butovich Bin Liu Jozsef Timar Wolfgang Hagmann 《Cancer metastasis reviews》1994,13(3-4):365-396
Arachidonic acid metabolites have been implicated in multiple steps of carcinogenesis. Their role in tumor cell metastasis, the ultimate challenge for the treatment of cancer patients, are however not well-documented. Arachidonic acid is primarily metabolized through three pathways, i.e., cyclooxygenase, lipoxygenase, and P450-dependent monooxygenase. In this review we focus our attention on one specific lipoxygenase, i.e., 12-lipoxygenase, and its potential role in modulating the metastatic process. In mammalian cells there exist three types of 12-lipoxygenases which differ in tissue distribution, preferential substrates, and profile of their metabolites. Most of these 12-lipoxygenases have been cloned and sequenced, and the molecular and biochemical determinants responsible for catalysis of specific substrates characterized. Solid tumor cells express 12-lipoxygenase mRNA, possess 12-lipoxygenase protein, and biosynthesize 12(S)-HETE [12(S)-hydroxyeicosatetraenoic acid], as revealed by numerous experimental approaches. The ability of tumor cells to generate 12(S)-HETE is positively correlated to their metastatic potential. A large collection of experimental data suggest that 12(S)-HETE is a crucial intracellular signaling molecule that activates protein kinase C and mediates the biological functions of many growth factors and cytokines such as bFGF, PDGF, EGF, and AMF. 12(S)-HETE plays a pivotal role in multiple steps of the metastatic cascade encompassing tumor cell-vasculature interactions, tumor cell motility, proteolysis, invasion, and angiogenesis. The fact that 12-lipoxygenase is expressed in a wide diversity of tumor cell lines and 12(S)-HETE is a key modulatory molecule in metastasis provides the rationale for targeting these molecules in anti-cancer and anti-metastasis therapeutic protocols. 相似文献